logo
  

Arvinas Stock Plunges 15%

Shares of Arvinas, Inc. (ARVN) are currently slipping nearly 15% on Monday morning. The company announced it has entered into neuroscience drug discovery collaboration with GNS Healthcare.

ARVN is currently trading at $39.00, down $6.68 or 14.62%, on the Nasdaq. The stock opened its trading at $40.82 after closing Friday's trading at $45.68.

GNS Healthcare and clinical-stage biotechnology company Arvinas has entered collaboration deal to create a new class of drugs based on targeted protein degradation, to generate insights to help accelerate drug development for neurodegenerative diseases.

For comments and feedback contact: editorial@rttnews.com

Business News

Looking to Invest in the Best Biotech Stocks? Subscribe to RTT Biotech Investor.
Follow RTT